Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pinacidil Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 known ✓ | O60706 | 9/20 | 0.53 |
| ▸ | KCNJ11 known ✓ | Q14654 | 9/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ABCC8 | Q09428 | 3/20 | 0.36 |
| ▸ | KCNJ8 | Q15842 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pinacidil Anhydrous SCHEMBL504208 | 1.00 | ABCC9 (0.53) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| Pinacidil Anhydrous SCHEMBL8478960 | 1.00 | ABCC9 (0.53) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| Pinacidil Anhydrous SCHEMBL9275522 | 1.00 | ABCC9 (0.53) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| Pinacidil Anhydrous SCHEMBL5051662 | 1.00 | ABCC9 (0.53) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| Pinacidil Anhydrous SCHEMBL7061536 | 0.92 | ABCC9 (0.46) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL9298624 | 0.84 | KIF11 (0.54) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL11158589 | 0.80 | ABCC9 (0.48) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL8141227 | 0.78 | KCNJ11 (0.39) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL24872316 | 0.77 | CYP3A4 (0.44) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL11164606 | 0.76 | CYP3A4 (0.41) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6539 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20260076961-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2026-03-19 | — | — | US | claimed |
| EP-4608405-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Veradermics, Incorporated (US) | 2025-09-03 | — | — | EP | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-12295368-B2 | Method for controlling hematophagous or sap-feeding arthropods | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSTIY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2025-05-13 | — | — | US | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| WO-2025078664-A1 | TREATMENT OF METASTATIC OR INVASIVE BRAIN CANCER | Celex Oncology Innovations Limited (GB) | 2025-04-17 | — | — | WO | claimed |
| EP-4536236-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | University of Utah Research Foundation (US) | 2025-04-16 | — | — | EP | claimed |
| WO-2025064646-A1 | COMPOSITIONS AND METHODS FOR WOUND HEALING AND HAIR GROWTH USING POLYELECTROLYTE COMPLEX (PEC) FILMS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-03-27 | — | — | WO | claimed |
| EP-0323745-A2 | Pharmaceutical preparations | BEECHAM GROUP PLC (GB) | 1989-07-12 | — | — | EP | claimed |
| EP-0302595-A2 | Pinacidil for treatment of pulmonary hypertension or right heart failure | BEECHAM GROUP PLC (GB) | 1989-02-08 | — | — | EP | claimed |
| US-4789679-A | Method for treating incontinence | BEECHAM GROUP P.L.C. (GB) | 1988-12-06 | — | — | US | claimed |
| EP-0271271-A2 | Pharmaceutical preparations | BEECHAM GROUP PLC (GB) | 1988-06-15 | — | — | EP | claimed |
| EP-0260790-A2 | Use of pinacidil in the treatment of incontinence | BEECHAM GROUP PLC (GB) | 1988-03-23 | — | — | EP | claimed |
| US-4720387-A | Sustained-release preparation of pinacidil | SHIONOGI & CO., LTD. (JP) | 1988-01-19 | — | — | US | claimed |
| EP-0223811-A1 | USE OF NICORANDIL OR PINACIDIL FOR THE TREATMENT OF PERIPHERAL VASCULAR DISEASE | BEECHAM GROUP PLC (GB) | 1987-06-03 | — | — | EP | claimed |
| EP-0207606-A2 | Use of pinacidil as an antiasthma agent | ELI LILLY AND COMPANY (US) | 1987-01-07 | — | — | EP | claimed |
| WO-1986006960-A2 | USE OF NICORANDIL OR PINACIDIL FOR THE TREATMENT OF PERIPHERAL VASCULAR DISEASE | BEECHAM GROUP P.L.C. (GB) | 1986-12-04 | — | — | WO | claimed |
| US-4617311-A | ADMINISTERING PINACIDIL | ELI LILLY AND COMPANY (US) | 1986-10-14 | — | — | US | claimed |